13F Holdings
中文EN

MBX MBX Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1776111 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-80.3%
TTM EPS YoY-139.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.7%
ROA-32.2%
ROIC (approx.)-53.3%
Asset turnover—

Leverage & solvency

Liabilities / assets5.5%
Debt / equity0.00x
Current ratio19.58x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue———
R&D expense$79.16M$57.41M$28.53M
SG&A expense$18.90M$10.78M$6.78M
Operating income-$98.06M-$68.19M-$35.31M
Pretax income-$87.00M-$61.90M—
Income tax$0$0$0
Net income-$86.97M-$61.92M-$32.56M
EBITDA-$97.81M-$67.95M-$35.15M
EPS (basic)-2.38-5.82-31.96
EPS (diluted)-2.38-5.82-31.96
Weighted avg. shares (diluted)36.51M10.64M1.02M
Balance sheet
Cash & equivalents$75.29M$49.35M$30.52M
Short-term investments$298.42M$212.80M$50.15M
Current assets$381.54M$267.29M$83.47M
PP&E, net$2.73M$1.08M$439,000
Total assets$385.14M$268.54M$84.18M
Current liabilities$15.49M$11.05M$3.93M
Total liabilities$15.92M$11.09M$4.29M
Shareholders' equity$369.22M$257.44M-$72.47M
Shares outstanding44.93M33.42M1.26M
Cash flow statement
Operating cash flow-$79.95M-$54.68M-$31.98M
Capital expenditure$1.93M$874,000$129,000
Free cash flow-$81.88M-$55.55M-$32.11M
Investing cash flow-$83.70M-$160.59M-$30.93M
Financing cash flow$189.59M$234.10M$69.22M
Depreciation & amortization$248,000$244,000$157,000
Stock-based compensation$8.68M$5.22M$2.04M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.